Previous 10 | Next 10 |
Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, announces the launch of its oncology and autoimmune discovery and development platform with an initial fo...
Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company focused on novel technologies including the targeting of oncological diseases, announced the results of it...
Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company focused on novel technologies including the targeting of oncological diseases, announced that it will hold...
Regulatory News: Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM), a clinical stage biopharmaceutical company focused on novel technologies including the targeting of oncological diseases, today announced that an interview with President Darren Lui will air on The RedChi...
Gainers: MNTV +14.5%. AUTL +10.9%. QDEL +7.8%. APM +6.7%. OLED +5.6%. Losers: ALLO -33.5%. CLLS -18.9%. MXCT -16.1%. CDAK -5.8%. CRBU -5.8%. For further details see: MNTV, AUTL, ALLO and CLLS among after hours movers
Gainers: ADVM +13.3%. SCPS +9.7%. BIDU +4.1%. AGTC +3.9%. APM +3.5%. Losers: HX -7.3%. NUVL -4.6%. RXRX -2.2%. FA -2.1%. FLYW -1.9%. For further details see: ADVM, SCPS, HX and NUVL among after hours movers
Regulatory News: Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM) (“Aptorum Group” or the “Company”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology and infectious diseases, today provided a busines...
Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company focused on novel technologies including the targeting of oncological diseases, announced that the group ha...
royaltystockphoto/iStock via Getty Images Aptorum Group ("APM") has announced additional positive phase 1 results for ALS-4, its candidate for Staphylococcus aureus. The new data for two additional cohorts shows that the drug was safe, well tolerated, with no serious adverse event. ALS-4 is a...
Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, announces further positive results of its ongoing Phase 1 clinical trial for ALS-4 (a first in-class anti...
News, Short Squeeze, Breakout and More Instantly...
Toronto, Ontario--(Newsfile Corp. - July 17, 2024) - Andean Precious Metals Corp. (TSXV: APM) (OTCQX: ANPMF) ( "Andean" or the "Company" ) will report its second quarter 2024 financial and operating results after market close on Tuesday, August 13, 2024. Management will host a conference call...
Toronto, Ontario--(Newsfile Corp. - July 16, 2024) - Andean Precious Metals Corp. (TSXV: APM) (OTCQX: ANPMF) ( "Andean" or the "Company" ) announced that it has engaged the services of ICP Securities Inc. ("ICP") to provide automated market making services, including use of its proprieta...
Toronto, Ontario--(Newsfile Corp. - July 11, 2024) - Andean Precious Metals Corp. (TSXV: APM) (OTCQX: ANPMF) ( "Andean" or the "Company" ) is pleased to announce the appointment of Sylvain Lessard as President and General Manager of Golden Queen Mine, effective today, July 11, 2024. Wi...